We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Henry Schien Buys North American Rescue, Expands Medical Arm
Read MoreHide Full Article
Henry Schien, Inc. (HSIC - Free Report) recently announced the completion of its acquisition of North American Rescue (NAR), a U.S.-based survivability and casualty-care medical products maker that caters to the defense and public-safety markets. This acquisition is expected to bolster Henry Schein Medical, the company’s medical business in the United States. This is also part of the company’s efforts to focus on adding more high-margin products to its portfolio.
The Deal at a Glance
Financial terms the deal, which was first announced in January, remain undisclosed. Henry Schein noted that NAR has a huge customer base and serves all branches of the U.S. military; various U.S. military departments and federal agencies; militaries of allied foreign countries; federal, state and local law enforcement departments; emergency medical service providers and fire departments plus community preparedness organizations including school districts besides commercial and community centers.
NAR provides products to treat and overcome the three most common causes of preventable combat deaths, namely hemorrhaging, tension pneumothorax and inadequate airway.
The company serves nearly 60% of its sales to the U.S. government. In fiscal 2018, NAR generated sales of approximately $184 million, reflecting a diversified portfolio of proprietary medical products.
Per Henry Schein, the deal is strategic and comes with a unique value proposition. The company believes that addition of NAR’s business will offer multiple areas with growth prospects and potential business synergies for Henry Schein Medical. Post integration, NAR will be able to sell more Henry Schein Medical and Henry Schein-branded products through its existing channels.
According to the company, NAR will help expand its Medical group geographic footprint, customer base, product offering and margins in both the United States and internationally, as it plans to advance the NAR business across the globe.
As stated earlier, Henry Schein expects NAR to be neutral to its 2019 earnings per share and be accretive thereafter.
Share Price Performance
Over the past six months, Henry Schein has underperformed its industry. The stock has plunged 31.7% against the 3.9% rise of the industry.
Key Picks
Henry Schien currently carries a Zacks Rank #5 (Strong Sell).
ABIOMED’s long-term earnings growth rate is expected at 27.67%.
Varian’s long-term earnings growth rate is projected at 8%.
Masimo’s long-term earnings are predicted to grow 15.60%.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.
Image: Bigstock
Henry Schien Buys North American Rescue, Expands Medical Arm
Henry Schien, Inc. (HSIC - Free Report) recently announced the completion of its acquisition of North American Rescue (NAR), a U.S.-based survivability and casualty-care medical products maker that caters to the defense and public-safety markets. This acquisition is expected to bolster Henry Schein Medical, the company’s medical business in the United States. This is also part of the company’s efforts to focus on adding more high-margin products to its portfolio.
The Deal at a Glance
Financial terms the deal, which was first announced in January, remain undisclosed. Henry Schein noted that NAR has a huge customer base and serves all branches of the U.S. military; various U.S. military departments and federal agencies; militaries of allied foreign countries; federal, state and local law enforcement departments; emergency medical service providers and fire departments plus community preparedness organizations including school districts besides commercial and community centers.
NAR provides products to treat and overcome the three most common causes of preventable combat deaths, namely hemorrhaging, tension pneumothorax and inadequate airway.
The company serves nearly 60% of its sales to the U.S. government. In fiscal 2018, NAR generated sales of approximately $184 million, reflecting a diversified portfolio of proprietary medical products.
Per Henry Schein, the deal is strategic and comes with a unique value proposition. The company believes that addition of NAR’s business will offer multiple areas with growth prospects and potential business synergies for Henry Schein Medical. Post integration, NAR will be able to sell more Henry Schein Medical and Henry Schein-branded products through its existing channels.
According to the company, NAR will help expand its Medical group geographic footprint, customer base, product offering and margins in both the United States and internationally, as it plans to advance the NAR business across the globe.
As stated earlier, Henry Schein expects NAR to be neutral to its 2019 earnings per share and be accretive thereafter.
Share Price Performance
Over the past six months, Henry Schein has underperformed its industry. The stock has plunged 31.7% against the 3.9% rise of the industry.
Key Picks
Henry Schien currently carries a Zacks Rank #5 (Strong Sell).
A few better-ranked stocks in the broader medical space are ABIOMED, Inc., , Varian Medical Systems, Inc. and Masimo, Inc. (MASI - Free Report) , each currently carrying a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
ABIOMED’s long-term earnings growth rate is expected at 27.67%.
Varian’s long-term earnings growth rate is projected at 8%.
Masimo’s long-term earnings are predicted to grow 15.60%.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>